Rheumatoid arthritis: Biological drugs and risk of infection

The Lancet

Volumn 386, Issue 9990, 2015, Pages 224-225

  Dixon, William G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

BIOLOGICAL THERAPY; DISEASE COURSE; HUMAN; INFECTION RISK; MONOTHERAPY; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT INDICATION; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; OPPORTUNISTIC INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; HUMANS; OPPORTUNISTIC INFECTIONS;

EID: 84937640319     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61907-3     Document Type: Note

References (9)

1. R Maini, EW St Clair, F Breedveld for the ATTRACT study group Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Lancet 354 1999 1932 1939
2. PE Lipsky, DM van der Heijde, EW St Clair for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 2000 1594 1602
3. T Bongartz, AJ Sutton, MJ Sweeting, I Buchan, EL Matteson, V Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2006 2275 2285
4. JP Leombruno, TR Einarson, EC Keystone The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Ann Rheum Dis 68 2009 1136 1145
5. AE Thompson, SW Rieder, JE Pope Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials Arthritis Rheum 63 2011 1479 1485
6. J Askling, W Dixon The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis Curr Opin Rheumatol 20 2008 138 144
7. A Strangfeld, M Eveslage, M Schneider et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70 2011 1914 1920
8. JA Singh, C Cameron, S Noorbaloochi et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis Lancet 2015 published online May 12. http://dx.doi.org/10.1016/S0140-6736(14)61704-9
9. A Zink, B Manger, J Kaufmann et al. Evaluation of the RABBIT risk score for serious infections Ann Rheum Dis 73 2013 1673 1676